Roche Molecular Diagnostics will develop diagnostic assays for Merck & Co. that will help the drug giant developer cancer drugs.
Financial terms of the deal between Pleasanton-based Roche Molecular Diagnostics and Merck (NYSE: MRK) were not disclosed.
No comments:
Post a Comment